Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ALX Oncology Holdings Inc. - Common Stock (NQ: ALXO )

1.620 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 1.620
Bid (Size) 1.550 (30)
Ask (Size) 1.710 (2)
Prev. Close 1.620
Today's Range 1.620 - 1.620
52wk Range 1.190 - 17.82
Shares Outstanding 40,869,135
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
From ALX Oncology
Via GlobeNewswire

Performance

YTD
-88.87%
-88.87%
1 Month
+14.89%
+14.89%
3 Month
-18.59%
-18.59%
6 Month
-75.27%
-75.27%
1 Year
-89.26%
-89.26%

More News

Read More
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference
From ALX Oncology
Via GlobeNewswire
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
From ALX Oncology
Via GlobeNewswire
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces November Investor Conference Participation
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
From ALX Oncology
Via GlobeNewswire
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q2 2024
Via InvestorPlace
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
From ALX Oncology
Via GlobeNewswire
Crude Oil Moves Lower; Moderna Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Dow Dips Over 500 Points; ISM Manufacturing PMI Falls In July
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq Surges 1%; Meta Posts Upbeat Earnings
Via Benzinga
Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients
Via Benzinga
Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
From ALX Oncology
Via GlobeNewswire
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
From ALX Oncology
Via GlobeNewswire
ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q1 2024
Via InvestorPlace
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.